Callio raises $187m for proof-of-concept for dual-payload ADC
Callio Therapeutics has raised $187m in Series A financing round for achieving clinical proof-of-concept for HER2-targeted…
Ozempic/Wegovy success triggers patent ‘gold rush’ for weight loss drugs – IAM
Ozempic/Wegovy success triggers patent ‘gold rush’ for weight loss drugs IAM
Are European biopharma manufacturers ‘nearshoring’?
Experts debate whether European manufacturers are preferring domestic operations as the continent competes with Asia and…
Shed Introduces Low-Dose Naltrexone (LDN) to Support Chronic Pain, Autoimmune Health, and Metabolism, Boosting Weight-Loss Solutions – PR Newswire
Shed Introduces Low-Dose Naltrexone (LDN) to Support Chronic Pain, Autoimmune Health, and Metabolism, Boosting Weight-Loss Solutions PR…
Woman suffers brain damage after taking weight-loss medicine sold on TikTok – VnExpress International
Woman suffers brain damage after taking weight-loss medicine sold on TikTok VnExpress International
South Africa’s Aspen aims for slice of booming GLP-1 drug market by 2026 – Reuters
South Africa’s Aspen aims for slice of booming GLP-1 drug market by 2026 Reuters
Reflecting on a milestone year for cell and gene therapies
Cell and gene therapies have undergone notable milestones in the last 12 months, with solid tumors…
Why Do Most People Quit Ozempic after Two Years? – Scientific American
Why Do Most People Quit Ozempic after Two Years? Scientific American
Why Do Most People Quit Ozempic after Two Years? – Scientific American
Why Do Most People Quit Ozempic after Two Years? Scientific American
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.